Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 7/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 5/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2955233 | 0.89 | KMT2A (0.51) | ROCK1ROCK2KMT2AMEN1MAPT | |
| SCHEMBL2961641 | 0.88 | KMT2A (0.45) | ROCK1ROCK2KMT2AMEN1MAPT | |
| SCHEMBL2957637 | 0.88 | KMT2A (0.45) | ROCK1ROCK2KMT2AMEN1MAPT | |
| SCHEMBL2959953 | 0.87 | KMT2A (0.44) | ROCK1ROCK2KMT2AMEN1MAPT | |
| SCHEMBL2961537 | 0.86 | KMT2A (0.42) | ROCK1ROCK2KMT2AMEN1MAPT | |
| SCHEMBL2961877 | 0.84 | KMT2A (0.45) | ROCK1ROCK2KMT2AMEN1MAPT | |
| SCHEMBL2953617 | 0.83 | KMT2A (0.40) | ROCK1ROCK2KMT2AMEN1MAPT | |
| SCHEMBL2953683 | 0.83 | ALDH1A1 (0.50) | ROCK1ROCK2KMT2AMEN1MAPT | |
| SCHEMBL2950908 | 0.83 | KMT2A (0.45) | ROCK1ROCK2KMT2AMEN1MAPT | |
| SCHEMBL2947767 | 0.81 | KMT2A (0.44) | ROCK1ROCK2KMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771425-B1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-05-14 | — | — | EP | claimed |
| US-20070179126-A1 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | US | claimed |
| US-7767681-B2 | 2-Carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-08-03 | — | — | US | disclosed |
| EP-1771425-B1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2008-05-14 | — | — | EP | disclosed |
| US-20070179126-A1 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2007-08-02 | — | — | US | disclosed |
| EP-1771425-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006016039-A1 | 2-CARBAMIDE-4-PHENYLTHIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2006-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179126-A1 | 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof | UGT2B7, PKD2, CYP2C19 | ROCK1 3931/4885ROCK2 2351/4885KMT2A 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.